A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis.

MLA

Yin, Jian, et al. “A Multicenter, Randomized, Open-Label, Phase 2 Clinical Study of Telitacicept in Adult Patients with Generalized Myasthenia Gravis.” European Journal of Neurology, vol. 31, no. 8, Aug. 2024, p. e16322. EBSCOhost, https://doi.org/10.1111/ene.16322.

APA

Yin, J., Zhao, M., Xu, X., Zhang, M., Xu, Z., Li, Z., Qin, X., Li, Z., Zhao, C., Zhou, H., Ma, Y., Cao, W., Wang, G., Lin, Y., Zhang, J., Zhang, X., Cai, H., Qian, W., Wang, Y., … Fang, J. (2024). A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. European Journal of Neurology, 31(8), e16322. https://doi.org/10.1111/ene.16322

Chicago

Yin, Jian, Mingming Zhao, Xianhao Xu, Meini Zhang, Zucai Xu, Zunbo Li, Xinyue Qin, et al. 2024. “A Multicenter, Randomized, Open-Label, Phase 2 Clinical Study of Telitacicept in Adult Patients with Generalized Myasthenia Gravis.” European Journal of Neurology 31 (8): e16322. doi:10.1111/ene.16322.